Aurinia Pharmaceuticals
AUPH
12 hedge funds and large institutions have $20.1M invested in Aurinia Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
8% less capital invested
Capital invested by funds: $21.7M → $20.1M (-$1.64M)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$2.26M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.77M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$21.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$404 |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$178 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.45M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$505K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.6K |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
AUPH Hedge Fund Activity: Q3 2015 in Review
12 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2015, worth a combined $20.1M — down 7.5% from $21.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AUPH and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $2.26M. The largest seller was RA Capital Management, exiting entirely with an estimated $3.45M sold.
- 12 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2015, down from 13 in Q2 2015.
- Funds reported $20.1M of Aurinia Pharmaceuticals stock for Q3 2015, down 7.5% quarter-over-quarter.
- 2 funds opened new Aurinia Pharmaceuticals positions in Q3 2015 and 3 closed out, a net change of -1 holder.
- The largest Aurinia Pharmaceuticals buyer in Q3 2015 was EverPoint Asset Management, an estimated $2.26M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2015 was RA Capital Management, an estimated $3.45M sold.
Based on aggregated 13F filings for Q3 2015.